- Home
- NAMI vs PRQR Comparison
NAMI vs PRQR Comparison
Compare NAMI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMI
- PRQR
- Stock Information
- Founded
- NAMI 2014
- PRQR 2012
- Country
- NAMI China
- PRQR Netherlands
- Employees
- NAMI N/A
- PRQR N/A
- Industry
- NAMI
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- NAMI
- PRQR Health Care
- Exchange
- NAMI NYSE
- PRQR Nasdaq
- Market Cap
- NAMI 286.0M
- PRQR 309.5M
- IPO Year
- NAMI 2024
- PRQR 2014
- Fundamental
- Price
- NAMI $5.19
- PRQR $2.80
- Analyst Decision
- NAMI
- PRQR Strong Buy
- Analyst Count
- NAMI 0
- PRQR 5
- Target Price
- NAMI N/A
- PRQR $7.60
- AVG Volume (30 Days)
- NAMI 519.9K
- PRQR 567.2K
- Earning Date
- NAMI 02-11-2025
- PRQR 11-07-2024
- Dividend Yield
- NAMI N/A
- PRQR N/A
- EPS Growth
- NAMI N/A
- PRQR N/A
- EPS
- NAMI 0.37
- PRQR N/A
- Revenue
- NAMI $56,127,097.00
- PRQR $20,506,357.00
- Revenue This Year
- NAMI N/A
- PRQR $235.11
- Revenue Next Year
- NAMI N/A
- PRQR N/A
- P/E Ratio
- NAMI $11.30
- PRQR N/A
- Revenue Growth
- NAMI 64.40
- PRQR 306.68
- 52 Week Low
- NAMI $3.75
- PRQR $1.61
- 52 Week High
- NAMI $7.75
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- NAMI N/A
- PRQR 40.12
- Support Level
- NAMI N/A
- PRQR $2.27
- Resistance Level
- NAMI N/A
- PRQR $2.95
- Average True Range (ATR)
- NAMI 0.00
- PRQR 0.28
- MACD
- NAMI 0.00
- PRQR -0.10
- Stochastic Oscillator
- NAMI 0.00
- PRQR 36.66
About NAMI JINXIN TECHNOLOGY HOLDING COMPANY SPONSORED ADS EACH REP 18 ORD SHS
Jinxin Technology Holding Co is a company which operates through its subsidiaries are principally engaged in provision of digital textbook subscription services in the People's Republic of China. The Company generates revenue by selling its content to hardware manufacturers in China whereby they are allowed to install the Company's digital educational content on the manufacturers' devices for sale to end users.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.